Covid-19 roundup: J&J part­ners with Catal­ent on 1B dose vac­cine goal; BioN­Tech, Pfiz­er be­gin mR­NA vac­cine tri­al in Ger­many

Sec­ond on­ly to the ques­tion of how you make a vac­cine work is how you make enough of them to match the im­me­di­ate glob­al de­mand any ap­proved prod­uct in­oc­u­la­tion will face.

BAR­DA has put mil­lions be­hind man­u­fac­tur­ing Mod­er­na’s can­di­date. Ox­ford has a large part­ner in In­dia. Cure­Vac has its own fac­to­ries and fund­ing to ex­pand. Sanofi is retro­fitting ex­ist­ing fa­cil­i­ties. Now J&J has un­veiled part of their man­u­fac­tur­ing an­swer, sign­ing a col­lab­o­ra­tion with Catal­ent, one of the largest bi­o­log­ics man­u­fac­tur­ers in the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER